Prostate Cancer Clinical Trial
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
Summary
The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.
Full Description
The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/surveys are being collected in: United States, Canada, UK, France, Spain, Japan, China and South Korea.
Eligibility Criteria
Inclusion Criteria:
For interviews (attribute prioritization and pretest interviews)
Diagnosis of mHSPC with or without previous experience with ADT
Able to read and understand the survey language
Able to provide informed consent For online survey
Diagnosis of mHSPC or locally-advanced prostate cancer with or without previous experience with ADT
Able to read and understand the survey language
Able to provide informed consent
Exclusion Criteria:
Not applicable
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Durham North Carolina, 27701, United States
How clear is this clinincal trial information?
